Reduced immune activity limits rejection of the implanted human colorectal cancer cells or tumor tissue. This permits the graft to survive and form a tumor within the animal, creating a living setting in which researchers can examine tumor growth and responses to experimental treatment rather than measuring activity only in isolated cells.
The resulting tumor can retain key features of colorectal carcinoma while growing in a living system. That preservation gives researchers a basis for relating treatment exposure to tumor behavior, including progression, delayed growth, or regression, and helps connect observations from the model with the biology of the implanted cancer.
Common outcomes identified for this model include tumor growth, drug exposure, therapeutic efficacy, and toxicity. Together, these measurements show not only whether an experimental treatment affects the tumor, but also whether the compound reaches a relevant biological setting and produces undesirable effects that should be considered before clinical studies.
They help connect a compound's chemical structure with biological activity by supplying measurable tumor responses in vivo. Researchers can compare experimental compounds through outcomes such as tumor regression or delayed progression, while also examining exposure, efficacy, and toxicity. This makes the model useful for prioritizing chemical candidates before clinical evaluation.
The workflow begins by implanting human colorectal cancer cells or tumor tissue into an immunodeficient animal. Researchers then allow the graft to form a tumor and evaluate its growth, drug exposure, response to experimental treatment, and toxicity. These observations provide the in vivo results used to assess a candidate treatment before clinical studies.
Researchers use colorectal carcinoma xenografts when they need evidence from a living system before clinical studies. The model is particularly relevant when evaluating how an experimental treatment affects tumor growth and whether it produces regression or delayed progression, while also recording drug exposure, therapeutic efficacy, and toxicity in the same research context.